SCHEMBL26962527

SCHEMBL26962527

CC(C)(C)OC(=O)N[C@H]1CSc2cc(F)c(N)cc2NC1=O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.41
▸ EPHX2 P34913 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35
▸ RELA Q04206 1/20 0.35
▸ IDO1 P14902 1/20 0.33
▸ CRBN Q96SW2 3/20 0.32
▸ HDAC1 Q13547 1/20 0.32
▸ HDAC8 Q9BY41 1/20 0.32
▸ HDAC6 Q9UBN7 1/20 0.32
▸ SCN9A Q15858 1/20 0.32
▸ CTSD P07339 2/20 0.31
▸ BACE1 P56817 2/20 0.31
▸ POLB P06746 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ AAK1 Q2M2I8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29796990 1.00 GAA (0.41) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL26962099 0.91 GAA (0.44) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL26961700 0.87 GAA (0.41) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL29796701 0.87 GAA (0.41) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL27121024 0.86 GAA (0.40) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL20263999 0.86 GAA (0.40) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL29797018 0.86 GAA (0.38) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL31374892 0.86 GAA (0.38) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL26961679 0.86 GAA (0.38) GAAEPHX2NFKB1NFKB2RELA
SCHEMBL29796978 0.85 GAA (0.40) GAAEPHX2NFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4291558-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2023-12-20 — — EP disclosed
CN-116964048-A Bicyclic tetrahydroazepine derivatives for the treatment of cancer 豪夫迈·罗氏有限公司 2023-10-27 — — CN disclosed
Send feedback